Search hospitals > Virginia > Norfolk

Virginia Oncology Associates

Claim this profile
Norfolk, Virginia 23502
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
228 reported clinical trials
9 medical researchers
Photo of Virginia Oncology Associates in NorfolkPhoto of Virginia Oncology Associates in NorfolkPhoto of Virginia Oncology Associates in Norfolk

Summary

Virginia Oncology Associates is a medical facility located in Norfolk, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Virginia Oncology Associates is involved with conducting 228 clinical trials across 127 conditions. There are 9 research doctors associated with this hospital, such as Michael A. Danso, Michael McCollum, Paul Conkling, MD, and Mark Fleming, MD.

Area of expertise

1Breast Cancer
Global Leader
Virginia Oncology Associates has run 59 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative
2Lung Cancer
Global Leader
Virginia Oncology Associates has run 36 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage I

Top PIs

Clinical Trials running at Virginia Oncology Associates

Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Pancreatic Cancer
Follicular Lymphoma
Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma
ALK Gene Rearrangement
Image of trial facility.

Sacituzumab Govitecan

for Triple-Negative Breast Cancer

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Image of trial facility.

Sacituzumab Govitecan + Pembrolizumab

for Triple-Negative Breast Cancer

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Image of trial facility.

Giredestrant + Phesgo

for Breast Cancer

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.
Recruiting2 awards Phase 311 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Virginia Oncology Associates?
Virginia Oncology Associates is a medical facility located in Norfolk, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Virginia Oncology Associates is involved with conducting 228 clinical trials across 127 conditions. There are 9 research doctors associated with this hospital, such as Michael A. Danso, Michael McCollum, Paul Conkling, MD, and Mark Fleming, MD.